益生菌作为疹的补充治疗的有效性和安全性:系统性审查和元分析
Danni Tan1, Ke Liao2, Yunfeng Yu1
1School of Traditional Chinese Medicine, Hunan University of Chinese Medicine, Changsha, China.
Frontiers in microbiology
|December 26, 2025
概括
益生菌在与抗组胺药物相结合时显著改善了疹的缓解和生活质量. 这种补充治疗也减少了不良事件和复发率,提供了一个有前途的治疗选择.
科学领域:
- 免疫学 免疫学 免疫学
- 胃肠病学 胃肠病学
- 皮肤病学 皮肤病学
背景情况:
- 疹治疗通常依赖抗组胺药物,但很大一部分患者会出现持续的症状.
- 益生菌作为治疗疹的辅助疗法的作用正在引起人们的兴趣,但强有力的证据有限.
- 需要对益生菌在疹管理中的有效性和安全性进行系统评估.
研究的目的:
- 进行元分析和试验序列分析 (TSA),评估益生菌作为疹的补充治疗方法的疗效和安全性.
- 评估益生菌对疹患者临床症状,生活质量和免疫标志物的影响.
主要方法:
- 对2025年4月30日之前发表的研究,在八个数据库中进行了系统的文献搜索.
- 包含1014名参与者的11项临床试验被纳入了元分析和TSA.
- 使用漏斗图和埃格尔测试来评估出版偏差;用GRADE系统评估证据确定性.
主要成果:
- 益生菌加抗胰岛素治疗显著改善了疹缓解率 (OR 2.90) 和干扰素- (IFN-γ) 水平 (MD 8.12) 与单独抗胰岛素相比.
- 这种组合疗法还导致皮疹活动评分 (UAS7) (MD -3.29),皮肤病生活质量指数 (DLQI) (MD -2.95) 和互白素-10 (IL-10) 水平 (MD -1.47) 的显著降低.
- 此外,益生菌降低了不良事件率 (OR 0.39) 和复发率 (OR 0.29),TSA证实了这些发现的稳定性.
结论:
- 益生菌作为补充性治疗疹的显著益处,改善了临床结果和患者的生活质量.
- 益生菌的使用也可以减少不良事件的发生,并减少疹的复发.
- 建议进行高质量的临床试验,以进一步验证这些发现,因为现有研究中存在潜在的偏差风险.
相关概念视频
01:26Peptic Ulcer Disease IV: Management
397
Medical treatment strategies for peptic ulcers encompass various methods. The primary goal of treatment is to diminish gastric acidity and strengthen mucosal defense mechanisms.
The therapeutic approach involves ensuring adequate rest, implementing drug therapy, promoting smoking cessation, making dietary modifications, and emphasizing long-term follow-up care.
Pharmacological management
The prevailing therapy for peptic ulcers involves a combination of managing the patient's current...
The therapeutic approach involves ensuring adequate rest, implementing drug therapy, promoting smoking cessation, making dietary modifications, and emphasizing long-term follow-up care.
Pharmacological management
The prevailing therapy for peptic ulcers involves a combination of managing the patient's current...
397
01:28Acid Suppressive Drugs for Peptic Ulcer Disease: Histamine H2-Receptor Antagonists
890
Histamine H2 receptors, which are intricately located on the basolateral membrane of parietal cells, play a crucial role in modulating gastric acid secretion. When released from enterochromaffin-like cells, histamine engages H2 receptors, initiating the cyclic AMP (cAMP) pathway. In this pathway, adenylyl cyclase converts ATP into cAMP, elevating intracellular cAMP levels. The activation of protein kinase A follows, stimulating the proton pump. This stimulation prompts the secretion of hydrogen...
890
01:25Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs
1.7K
Asthma is a chronic respiratory condition for which new therapeutic avenues, including anti-inflammatory drugs like mast cell stabilizers and anti-IgE treatments, continue to be developed.
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
1.7K
01:19Antiasthma Drugs: Leukotriene Modifiers
1.7K
Leukotriene modifiers, or cysteinyl leukotriene receptor antagonists, are medications used to manage chronic asthma. These agents target specific inflammatory mediators produced during arachidonic acid metabolism, an essential process in generating inflammation in the body.
Leukotriene modifiers work through two distinct mechanisms:
Leukotriene modifiers work through two distinct mechanisms:
1.7K